HER2 Positive Metastatic Breast Cancer Clinical Trial
Official title:
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd
A Global, Single Arm, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd. The ARX788 will be administered every 3 weeks (Q3W) intravenous (IV) infusion. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03691051 -
A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03080805 -
Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)
|
Phase 3 | |
| Active, not recruiting |
NCT02422199 -
A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab
|
Phase 1/Phase 2 | |
| Terminated |
NCT01495884 -
The Myocet/Lapatinib Study. ICORG 10-03, V5
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02973737 -
A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer
|
Phase 3 | |
| Completed |
NCT04398108 -
A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC
|
Phase 1 | |
| Active, not recruiting |
NCT04681287 -
Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.
|
Phase 2 |